Rachel Holloway

Rachel Holloway serves as a key procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of scientific and operational resources. She manages complex contracting actions centered on research and development in the life sciences, with a focus on enabling laboratory diagnostics, infectious disease surveillance, and data-driven public health response capabilities. Her portfolio includes high-priority acquisitions for biomedical tools, diagnostic platforms, and analytical systems critical to national health security. Holloway works closely with technical stakeholders to translate scientific requirements into compliant, performance-based solicitations that ensure rapid deployment of mission-critical capabilities. She maintains longstanding relationships with leading contractors including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, and Cepheid, partnering with organizations that deliver advanced diagnostic technologies, clinical research support, and public health infrastructure solutions. Her procurement approach emphasizes technical rigor, regulatory compliance, and lifecycle performance, often engaging vendors with proven expertise in biosafety level 3/4 environments, molecular diagnostics, and epidemiological data systems. These partnerships are typically structured as cost-reimbursement or fixed-price contracts tailored to high-complexity, mission-essential deliverables. Holloway’s contracting activity reflects a strong preference for full and open competition, with no set-asides applied across her portfolio. This aligns with CDC’s need for specialized, large-scale capabilities that often exceed the capacity of small business concerns in this highly technical domain. While socioeconomic set-asides are not utilized, her work ensures equitable access through transparent, merit-based evaluations grounded in technical excellence and operational readiness. Her primary focus lies in NAICS 541715—Research and Development in the Physical, Engineering, and Life Sciences—where she procures advanced laboratory instrumentation, genomic sequencing systems, infectious disease detection platforms, and integrated data analytics tools. Her expertise spans biosurveillance, clinical diagnostics, and public health informatics, ensuring acquisitions directly support CDC’s frontline response to emerging health threats.